AXDX 📈 Accelerate Diagnostics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00430H1023
AXDX: Diagnostic Platform, Test Kits
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Web URL: https://acceleratediagnostics.com
Additional Sources for AXDX Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AXDX Stock Overview
Market Cap in USD | 38m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1996-11-18 |
AXDX Stock Ratings
Growth 5y | -77.4% |
Fundamental | -18.5% |
Dividend | - |
Rel. Strength Industry | -2154 |
Analysts | 5/5 |
Fair Price Momentum | 0.45 USD |
Fair Price DCF | - |
AXDX Dividends
No Dividends PaidAXDX Growth Ratios
Growth Correlation 3m | -73.8% |
Growth Correlation 12m | 42.7% |
Growth Correlation 5y | -96% |
CAGR 5y | -63.34% |
CAGR/Mean DD 5y | -0.83 |
Sharpe Ratio 12m | -0.90 |
Alpha | -114.74 |
Beta | 1.72 |
Volatility | 92.73% |
Current Volume | 384.8k |
Average Volume 20d | 86.2k |
What is the price of AXDX stocks?
As of December 30, 2024, the stock is trading at USD 1.10 with a total of 384,762 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -33.73%, over three months by -35.67% and over the past year by -71.94%.
As of December 30, 2024, the stock is trading at USD 1.10 with a total of 384,762 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -33.73%, over three months by -35.67% and over the past year by -71.94%.
Is Accelerate Diagnostics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Accelerate Diagnostics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AXDX as of December 2024 is 0.45. This means that AXDX is currently overvalued and has a potential downside of -59.09%.
Neither. Based on ValueRay Fundamental Analyses, Accelerate Diagnostics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AXDX as of December 2024 is 0.45. This means that AXDX is currently overvalued and has a potential downside of -59.09%.
Is AXDX a buy, sell or hold?
Accelerate Diagnostics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AXDX.
Accelerate Diagnostics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AXDX.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for AXDX stock price target?
According to ValueRays Forecast Model, AXDX Accelerate Diagnostics will be worth about 0.5 in December 2025. The stock is currently trading at 1.10. This means that the stock has a potential downside of -54.55%.
According to ValueRays Forecast Model, AXDX Accelerate Diagnostics will be worth about 0.5 in December 2025. The stock is currently trading at 1.10. This means that the stock has a potential downside of -54.55%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1.5 | 36.4% |
Analysts Target Price | 9 | 718.2% |
ValueRay Target Price | 0.5 | -54.5% |